Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cozad Asset Management Inc.

Cozad Asset Management Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,658 shares of the biopharmaceutical company’s stock after selling 3,185 shares during the period. Cozad Asset Management Inc.’s holdings in Gilead Sciences were worth $5,643,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Clearbridge Investments LLC grew its holdings in shares of Gilead Sciences by 179.0% during the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after purchasing an additional 2,915,141 shares during the last quarter. abrdn plc grew its holdings in shares of Gilead Sciences by 89.0% during the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after purchasing an additional 1,772,887 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $133,584,000. AEGON ASSET MANAGEMENT UK Plc purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $63,971,000. Finally, Bailard Inc. grew its holdings in shares of Gilead Sciences by 9,100.7% during the third quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock worth $54,133,000 after buying an additional 714,494 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GILD. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, April 24th. Mizuho lowered their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $83.60.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.62 during midday trading on Tuesday, reaching $65.32. 1,975,856 shares of the company traded hands, compared to its average volume of 7,413,350. The firm’s 50 day simple moving average is $71.16 and its two-hundred day simple moving average is $76.17. Gilead Sciences, Inc. has a 1-year low of $64.63 and a 1-year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The firm has a market cap of $81.33 billion, a PE ratio of 183.17, a price-to-earnings-growth ratio of 1.29 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the previous year, the firm posted $1.37 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.82 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.72%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.